Cardiovascular risk in menopausal women and our evolving understanding of menopausal hormone therapy: risks,...

Area of Science:

• Cardiology
• Endocrinology
• Women's Health

Background:

• Women face a higher risk of cardiovascular disease (CVD) than men, with increased prevalence at midlife suggesting a role for menopause.
• Declining hormone levels during menopause may influence CVD risk factors, leading to the exploration of menopause hormone therapies (MHT).

Purpose of the Study:

• To review traditional and sex-specific CVD risk factors in women, focusing on menopause.
• To evaluate the cardiovascular effects of MHT by analyzing landmark clinical trials.
• To summarize MHT guidelines and propose strategies for reducing cardiovascular risk in women.

Main Methods:

• Literature review of traditional and sex-specific CVD risk factors in women.
• Analysis of cardiovascular effects of MHT through landmark clinical trials.
• Synthesis of current guidelines for MHT use and risk management strategies.

Main Results:

• MHT has not consistently demonstrated cardiovascular benefits and has been associated with significant risks in clinical trials.
• The timing of MHT administration appears critical in determining its relative risks and benefits.
• Current guidelines do not recommend MHT for primary or secondary prevention of CVD.

Conclusions:

• MHT is not currently recommended for cardiovascular disease prevention in women.
• Cardiovascular risks must be carefully considered before prescribing MHT for menopausal symptoms or bone health.
• Further research is needed on MHT routes, dosing, and formulations to determine optimal timing for administration.